Prosecution Insights
Prosecution Insights
10 pending office actions • 5 clients • 9 examiners • 9 art units • 0 of 10 (0%) have an AI response strategy ready • 10 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 6 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 6 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 4 (40%) |
| §112 only | 1 (10%) |
| Double-patenting + other | 1 (10%) |
| Multi-statute (no §101) | 4 (40%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| PIHONAK, SARAH | 2 | 61.1% | +42.9% |
| MARONEY, JENNA M | 1 | 64.5% | +20.4% |
| RAMACHANDRAN, UMAMAHESWARI | 1 | 54.5% | +53.9% |
| JAVANMARD, SAHAR | 1 | 65.3% | +34.8% |
| MCKNIGHT, CIARA A | 1 | 59.2% | +38.1% |
| TCHERKASSKAYA, OLGA V | 1 | 55.3% | +46.2% |
| FAY, ZOHREH ALEMZADEH | 1 | 52.0% | -6.2% |
| CLARKE, TRENT R | 1 | 41.3% | +25.1% |
| MCMILLIAN, KARA RENITA | 1 | 30.4% | +37.9% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18212720 | Medical Treatments Based on Anamorelin | JAVANMARD, SAHAR | 59d overdue |
| 18198266 | Manufacturing Process for Metaxalone Tablets | TCHERKASSKAYA, OLGA V | 12d |
| 18704848 | HIGH PURITY NON-ANIMAL DERIVED UDCA | RAMACHANDRAN, UMAMAHESWARI | — |
| 18038203 | ENZYMATIC METHODS FOR CONVERTING LCA AND 3-KCA TO UDCA AND 3-KUDCA | MCKNIGHT, CIARA A | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18212720 | Medical Treatments Based on Anamorelin | JAVANMARD, SAHAR | 59d overdue |
| 17911429 | OPHTHALMIC CHLOROPROCAINE GEL HAVING IMPROVED FUNCTIONALITY | MCMILLIAN, KARA RENITA | 6d |
| 18198266 | Manufacturing Process for Metaxalone Tablets | TCHERKASSKAYA, OLGA V | 12d |
| 19347686 | PHYSIOLOGICALLY BALANCED INJECTABLE FORMULATIONS OF FOSNETUPITANT | PIHONAK, SARAH | 35d |
| 18009057 | GENETICALLY MODIFIED ORGANISMS FOR THE PRODUCTION OF STEROID DERIVATIVES | CLARKE, TRENT R | 70d |
| 18827752 | METHODS OF BUTANE DELIVERY | MARONEY, JENNA M | — |
| 18704848 | HIGH PURITY NON-ANIMAL DERIVED UDCA | RAMACHANDRAN, UMAMAHESWARI | — |
| 18215170 | METHODS OF TREATING NEUROINFLAMMATION AND INHIBITING MONOAMINE OXIDASE-A AND RESTORING/UPREGULATING/INCREASING IL-13 AND AND PGC-1 BY ADMINISTERING ORAL DOSAGE FORM CONTAINING MICRONIZED AND NONMICRONIZED PARTICULATE METAXALONE, ALGINIC ACID AND PROPYLENE GLYCOL ALGINATE | PIHONAK, SARAH | — |
| Client (Assignee) | Pending OAs |
|---|---|
| Sandhill One, LLC | 3 |
| Helsinn Healthcare | 2 |
| Primus Pharmaceuticals, Inc. | 2 |
| SINTETICA S.A. | 2 |
| Texon Midstream, LLC | 1 |
| Art Unit | Apps |
|---|---|
| 1627 | 2 |
| 3763 | 1 |
| 1629 | 1 |
| 1622 | 1 |
| 1656 | 1 |
| 1615 | 1 |
| 1617 | 1 |
| 1651 | 1 |
| 1623 | 1 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 19347686 | PHYSIOLOGICALLY BALANCED INJECTABLE FORMULATIONS OF FOSNETUPITANT | Helsinn Healthcare SA | PIHONAK, SARAH | 1627 | §103DP | Non-Final OA | 35d | Pending | Oct 01, 2025 |
| 18827752 | METHODS OF BUTANE DELIVERY | Texon Midstream, LLC | MARONEY, JENNA M | 3763 | §112 | Non-Final OA | — | Pending | Sep 08, 2024 |
| 18704848 | HIGH PURITY NON-ANIMAL DERIVED UDCA | Sandhill One, LLC | RAMACHANDRAN, UMAMAHESWARI | 1629 | §102§103§112 | Non-Final OA | — | Pending | Apr 25, 2024 |
| 18215170 | METHODS OF TREATING NEUROINFLAMMATION AND INHIBITING MONOAMINE OXIDASE-A AND RESTORING/UPREGULATING/INCREASING IL-13 AND AND PGC-1 BY ADMINISTERING ORAL DOSAGE FORM CONTAINING MICRONIZED AND NONMICRONIZED PARTICULATE METAXALONE, ALGINIC ACID AND PROPYLENE GLYCOL ALGINATE | Primus Pharmaceuticals, Inc. | PIHONAK, SARAH | 1627 | §103 | Non-Final OA | — | Pending | Jun 28, 2023 |
| 18212720 | Medical Treatments Based on Anamorelin | Helsinn Healthcare SA | JAVANMARD, SAHAR | 1622 | §102§103 | Non-Final OA | 59d overdue | Pending | Jun 22, 2023 |
| 18038203 | ENZYMATIC METHODS FOR CONVERTING LCA AND 3-KCA TO UDCA AND 3-KUDCA | Sandhill One, LLC | MCKNIGHT, CIARA A | 1656 | §102§103§112 | Non-Final OA | — | Pending | May 22, 2023 |
| 18198266 | Manufacturing Process for Metaxalone Tablets | Primus Pharmaceuticals, Inc. | TCHERKASSKAYA, OLGA V | 1615 | §103§112 | Final Rejection | 12d | Pending | May 16, 2023 |
| 18032188 | STABLE, INJECTABLE NORADRENALINE SOLUTIONS FREE OF ANTIOXIDANTS | Sintetica S.A. | FAY, ZOHREH ALEMZADEH | 1617 | §103 | Non-Final OA | 14d | Pending | Apr 17, 2023 |
| 18009057 | GENETICALLY MODIFIED ORGANISMS FOR THE PRODUCTION OF STEROID DERIVATIVES | Sandhill One, LLC | CLARKE, TRENT R | 1651 | §103 | Final Rejection | 70d | Pending | Dec 08, 2022 |
| 17911429 | OPHTHALMIC CHLOROPROCAINE GEL HAVING IMPROVED FUNCTIONALITY | Sintetica S.A. | MCMILLIAN, KARA RENITA | 1623 | §103Other | Final Rejection | 6d | Pending | Sep 14, 2022 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial